Fig 1.
Study design and participants included in the study.
TSM: Talaromycosis marneffei, IRIS: immune reconstitution inflammatory syndrome.
Table 1.
Clinical manifestations related to TSM-associated IRIS in IRIS group.
Fig 2.
Histogram showing the number of patients who developed IRIS over time after ART initiation.
Fig 3.
Comparisons of laboratory variables at baseline, ART initiation, and IRIS onset in IRIS group.
Significant differences (P < 0.05) between different time points are indicated. ART; antiretroviral therapy; IRIS, immune reconstitution inflammatory syndrome. CRP: C-reactive protein, WBC: white blood cell, MONO: monocytes, HGB: hemoglobin, PLT: platelets, PCT: procalcitonin, ALB: albumin, ALT: alanine aminotransferase, AST: aspartate aminotransferase.
Table 2.
Baseline demographic and clinical characteristics of IRIS group and non-IRIS group.
Table 3.
Comparison of laboratory results between IRIS and non-IRIS groups at IRIS onset.
Fig 4.
The comparison of CD4+ count, CD4/CD8 ratio, and HIV RNA load levels.
(A). CD4+ count at baseline and IRIS onset. (B). Increase in CD4+ count from baseline to IRIS onset. (C). CD4+/CD8+ ratio at baseline and IRIS onset. (D). Increase in CD4+/CD8+ ratio from baseline to IRIS onset. (E). HIV RNA load at baseline and IRIS onset. (F). Decrease in HIV RNA load from baseline to IRIS onset. ART: antiretroviral therapy, IRIS: immune reconstitution inflammatory syndrome.
Table 4.
Comparison of the hospitalization duration, readmission rate, and mortality rate between IRIS and non-IRIS groups.